ViroPharma, Inc.

  • Breakups Are Always Bad

    By usman iftikhar - August 5, 2013 | Tickers: HALO, VPHM

    Last week both ViroPharma (NASDAQ: VPHM) and Halozyme Therapeutics (NASDAQ: HALO) experienced a major decline in their stock prices. This was the aftermath of ViroPharma’s decision to discontinue the Phase II study program which involved Cinryze, and Halozyme’s recombinant human enzyme technology. Both the companies experienced a sharp decline in their share prices so I wanted to see which of them would be able to rise again.

    ViroPharma more »

  • Who Stands to Lose the Most From This Biotech Breakup?

    By Leo Sun - August 2, 2013 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    Shares of ViroPharma (NASDAQ: VPHM) and Halozyme Therapeutics (NASDAQ: HALO) dropped in tandem on August 1, after ViroPharma discontinued a Phase II study of administering its flagship drug, Cinryze, subcutaneously with Halozyme’s recombinant human enzyme technology. ViroPharma shares declined nearly 7% after the announcement, but Halozyme plunged almost 14%, due to ViroPharma’s statement that it would pursue similar studies for subcutaneous injection by using other products, which raised more »

  • An Interesting Bio Play in the Blood Disorder Niche

    By Kanak Kanti - July 1, 2013 | Tickers: DYAX, HALO, SHPG, VPHM

    Thousands of Americans suffer from a rare and painful disease every year. This inherited disease is called Hereditary Angioedema, or HAE for short. Its most effective treatment is about to become more convenient than ever, and the company that makes this possible could reap rich rewards.

    There are only five approved drugs for the disease: SC injections Kalbitor from Dyax (NASDAQ: DYAX) and Firazyr from Shire Plc (NASDAQ: SHPG), and more »

  • Healthcare-Focused Hedgie Bullish on These Stocks

    By Meena Krishnamsetty - April 18, 2013 | Tickers: CYBX, ONXX, QCOR, UTHR, VPHM

    To say that William Leland Edwards of Palo Alto Investors invests heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »

  • Healthcare-Focused Hedgie Bullish On These Stocks

    By Meena Krishnamsetty - April 16, 2013 | Tickers: CYBX, ONXX, QCOR, UTHR, VPHM

    To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »

  • Pfizer’s Backing Spurs Halozyme's Growth

    By Josef Ray Dagatan - December 27, 2012 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    An upcoming partnership with pharmaceutical giant Pfizer undoubtedly boosted the reputation of Halozyme Therapeutics (NASDAQ: HALO), allowing it to regain market standing via its proprietary Enhanze technology. Intraday trading this past Friday, December 21, saw shares rise around thirty percent, and prices grow by almost the same percentage when it went up by $1.49 and closed at $7.01, making it the day’s top-dollar gainer.

    The licensing agreement more »

  • This Hedge Fund's Picks Have Returned 20% Two Straight Quarters

    By Meena Krishnamsetty - November 6, 2012 | Tickers: AUXL, CYBX, MRX, ONXX, VPHM

    We track over 400 funds and investors, and have calculated the value-weighted returns for all funds in the 1500 largest stocks, while compiling a list of the top performing funds for the first three quarters of 2012. The returns are based on the fund’s 13F long positions only, as we do not have access to their short positions.

    Palo Alto has done it again, finishing in the top five more »

  • Buyout Rumors Highlight Watson Pharmaceuticals

    By Bobbie Johnson - April 26, 2012 | Tickers: ACT, NVS, RHHBY, TEVA, VPHM

    Earlier this year whispers of a Watson Pharmaceuticals (NYSE: ACT) deal began surfacing and they don’t seem to be letting up.  Watson is close to making the biggest buyout the company has ever seen.

    The generic drug maker is close to announcing, according to reports, the $6 billion acquisition of Actavis, a Swiss drug maker, by the end of the month. Should the deal go through, the combination will more »

  • Stock Upgrades And Downgrades From 2011/12/15

    By DividendYields - December 16, 2011 | Tickers: ANIP, BWA, CTAS, CCNE, FSLR, ITC, KIOR, LRCX, LEAP, LUFK.DL, LAVA, NYCB, NVLS, SWKS, TMUS, TE, VPHM

    Upgrades and downgrades are positive (negative) changes in the rating of a security. An upgrade is usually triggered by a steady improvement in the fundamentals and financials of the entity that has issued the security. Downgrade ratings are vice versa. Changes in the analyst rating could hit the company’s stock price significantly. Watch out the current rating decisions. Here is a current list of recent company upgrades and downgrades more »